| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
14 |
| Employees |
20 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-19 |
| Cash Flow (TTM) (Millions $) |
12 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Biophytis SA is a clinical-stage biotechnology company based in France. The company focuses on developing innovative therapeutics to treat age-related diseases, with a particular focus on neuromuscular and metabolic diseases. Biophytis is known for its expertise in the field of mitochondria, which are often implicated in age-related conditions.
The company's lead product candidate is Sarconeos (BIO101), which is being developed for the treatment of sarcopenia, a progressive decline in muscle mass, strength, and function that occurs with aging. Sarconeos is currently in Phase 2b/3 clinical trials and has shown promising results in improving muscle function in patients with sarcopenia.
Biophytis has also developed other drug candidates targeting various age-related diseases, including Macuneos (BIO201) for the treatment of dry age-related macular degeneration and COVA (BIO34) for the treatment of COVID-19 patients with respiratory failure. These drug candidates are in preclinical or early clinical stages of development.
Overall, Biophytis SA is dedicated to advancing the field of biotechnology and developing innovative therapies to address the unmet needs of aging populations.
Company Address: Sorbonne University—BC 9 Paris 75005
Company Phone Number: 1 44 27 23 00 Stock Exchange / Ticker: NASDAQ BPTS
|
%
4.2% 